Phreesia (PHR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

$30,000 of PHREESIA INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Lobbying related to patient reported quality ...

Phreesia stock opened at $27.12 on Thursday. The company’s 50-day moving average price is $23.18 and its 200-day moving average price is $22.71. The company has a quick ratio of 1.77, a current ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on PHR: Phreesia NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Even though Visual Look Up can be very useful, some people might consider it a hidden iPhone feature, as it's really easy to ...

Despite spending hours behind the wheel, most drivers remain clueless about certain dashboard warning symbols. One such ...

Phreesia (PHR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock ...

KeyBanc raised the firm’s price target on Phreesia (PHR) to $30 from $28 and keeps an Overweight rating on the shares. The firm notes healthcare technology stocks were under pressure for most of ...

76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 92.1% of Phreesia shares are owned by institutional investors. 6.1% of OptimizeRx shares are owned by insiders.

Analyst Price Forecast Suggests 8.40% Upside As of December 24, 2024, the average one-year price target for Phreesia is $30.82/share. The forecasts range from a low of $24.24 to a high of $37.80.